Luteinizing hormone-releasing hormone antagonists for urinary obstruction in prostate cancer

Authors

  • Patricia Tai Department of Radiation Oncology, Allan Blair Cancer Centre, Regina, SK
  • Asim Amjad Department of Radiation Oncology, Allan Blair Cancer Centre, Regina, SK
  • Rashmi Koul Department of Radiation Oncology, Allan Blair Cancer Centre, Regina, SK
  • Evgeny Sadikov Department of Radiation Oncology, Allan Blair Cancer Centre, Regina, SK
  • Arbind Dubey Department of Radiation Oncology, Allan Blair Cancer Centre, Regina, SK

DOI:

https://doi.org/10.5489/cuaj.412

Abstract

Luteinizing hormone-releasing hormone (LHRH) antagonists rapidly reduce testosterone and are preferred to LHRH agonists in situations when early response is important. The lack of flare reaction, as compared to LHRH agonists, is particularly desirable as it would not aggravate the problem. A 78-year-old man presented with symptoms of urinary tract obstruction. He had a prostate-specific antigen (PSA) of 91.3 ug/L and serum creatinine 146 umol/L. He had a large pelvic mass due to histologically confirmed prostate cancer, resulting in moderate left hydronephrosis and deteriorating renal function (serum creatinine of 163 umol/L). He was started on combined degarelix and bicalutamide on the day of consultation (day 0). The hydronephrosis resolved on the repeat computerized tomography scan performed on day 10. Serum creatinine normalized to under 130 umol/L on day 18. The PSA fell to 11 ug/L on day 18, 2.8 ug/L on day 28, and 0.5 ug/L on day 53. Therefore, LHRH antagonists are particularly useful in urgent situations. It is the preferred choice in these circumstances.

Downloads

Download data is not yet available.

Downloads

Published

2013-10-09

How to Cite

Tai, P., Amjad, A., Koul, R., Sadikov, E., & Dubey, A. (2013). Luteinizing hormone-releasing hormone antagonists for urinary obstruction in prostate cancer. Canadian Urological Association Journal, 7(9-10), e648–50. https://doi.org/10.5489/cuaj.412

Issue

Vol. 7 No. 9-10 (2013): CUAJ October

Section

Case Report

License

You, the Author(s), assign your copyright in and to the Article to the Canadian Urological Association. This means that you may not, without the prior written permission of the CUA:

  • Post the Article on any Web site
  • Translate or authorize a translation of the Article
  • Copy or otherwise reproduce the Article, in any format, beyond what is permitted under Canadian copyright law, or authorize others to do so
  • Copy or otherwise reproduce portions of the Article, including tables and figures, beyond what is permitted under Canadian copyright law, or authorize others to do so.

The CUA encourages use for non-commercial educational purposes and will not unreasonably deny any such permission request.

You retain your moral rights in and to the Article. This means that the CUA may not assert its copyright in such a way that would negatively reflect on your reputation or your right to be associated with the Article.

The CUA also requires you to warrant the following:

  • That you are the Author(s) and sole owner(s), that the Article is original and unpublished and that you have not previously assigned copyright or granted a licence to any other third party;
  • That all individuals who have made a substantive contribution to the article are acknowledged;
  • That the Article does not infringe any proprietary right of any third party and that you have received the permissions necessary to include the work of others in the Article; and
  • That the Article does not libel or violate the privacy rights of any third party.